Lim J, Yong Y, Dewi F, Chan S, Lim V
Drug Deliv Transl Res. 2025; .
PMID: 39955406
DOI: 10.1007/s13346-025-01790-3.
Chen M, He K, Wang K, Cai Y, Ying Z, Li X
PLoS One. 2025; 20(2):e0313649.
PMID: 39932912
PMC: 11813107.
DOI: 10.1371/journal.pone.0313649.
Abdel-Megeed R, Abdel-Hamid A, Kadry M
Toxicol Rep. 2025; 14():101869.
PMID: 39811821
PMC: 11731616.
DOI: 10.1016/j.toxrep.2024.101869.
Buchalska B, Kaminska K, Kowara M, Sobiborowicz-Sadowska A, Cudnoch-Jedrzejewska A
Cardiovasc Toxicol. 2025; 25(2):248-268.
PMID: 39810066
DOI: 10.1007/s12012-024-09952-4.
Scott N, Kang S, Parekh S
Sci Adv. 2024; 10(51):eadr5947.
PMID: 39693448
PMC: 11654694.
DOI: 10.1126/sciadv.adr5947.
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.
Meinag F, Fatahi M, Vahedian V, Maroufi N, Mosayyebi B, Ahmadi E
Funct Integr Genomics. 2024; 24(5):150.
PMID: 39222264
DOI: 10.1007/s10142-024-01431-x.
UNC13B regulates the sensitivity of Wilms' tumor cells to doxorubicin by modulating lysosomes.
Chen X, Bao Y, Sun G, Wang X, Zhu J
Oncol Lett. 2024; 28(3):446.
PMID: 39091580
PMC: 11292464.
DOI: 10.3892/ol.2024.14579.
OIP5-AS1 enhances the malignant characteristics and resistance to chemotherapy of pancreatic cancer cells by targeting miR-30d-5p/MARCH8.
Ying L, Li K, Chen C, Wang Y, Zhao Q, Wang Y
Heliyon. 2024; 10(13):e33835.
PMID: 39050450
PMC: 11268210.
DOI: 10.1016/j.heliyon.2024.e33835.
Photoactive metabolite mediated photodynamic therapy of Rhabdomyosarcoma cell lines using medicinal plants and Doxorubicin co-treatments.
Javaid S, Qureshi I, Khurshid A, Afsar T, Husain F, Khurshid M
BMC Complement Med Ther. 2024; 24(1):270.
PMID: 39010043
PMC: 11251096.
DOI: 10.1186/s12906-024-04575-2.
Assessing genotoxic effects of chemotherapy agents by a robust assay based on mass spectrometric quantification of γ-H2AX in HepG2 cells.
Qu M, Chen J, Xu B, Shi Q, Zhao S, Wang Z
Front Pharmacol. 2024; 15:1356753.
PMID: 38962306
PMC: 11219945.
DOI: 10.3389/fphar.2024.1356753.
Tumor microenvironment responsive nano-herb and CRISPR delivery system for synergistic chemotherapy and immunotherapy.
Jia Y, Yao Y, Fan L, Huang Q, Wei G, Shen P
J Nanobiotechnology. 2024; 22(1):346.
PMID: 38898493
PMC: 11186293.
DOI: 10.1186/s12951-024-02571-9.
Doxorubicin-induced neurotoxicity differently affects the hippocampal formation subregions in adult mice.
Dias-Carvalho A, Ferreira M, Reis-Mendes A, Ferreira R, Bastos M, Fernandes E
Heliyon. 2024; 10(11):e31608.
PMID: 38868005
PMC: 11168325.
DOI: 10.1016/j.heliyon.2024.e31608.
SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma.
Zhou P, Yao W, Liu L, Yan Q, Chen X, Wei X
Cell Oncol (Dordr). 2024; 47(5):1757-1778.
PMID: 38753154
DOI: 10.1007/s13402-024-00955-5.
Unveiling the anticancer potential of the ethanolic extract from .
Oliveira A, De Oliveira F, Braz A, Oliveira J, Lima-Santos J, Dias A
Front Pharmacol. 2024; 15:1398135.
PMID: 38751785
PMC: 11094271.
DOI: 10.3389/fphar.2024.1398135.
Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma.
Seo K, Hwang K, Nam K, Kim M, Song Y, Kim C
Pharmaceutics. 2024; 16(4).
PMID: 38675227
PMC: 11055028.
DOI: 10.3390/pharmaceutics16040566.
Biodegradable Microspheres for Transarterial Chemoembolization in Malignant Liver Disease.
Moschovaki-Zeiger O, Arkoudis N, Giannakis A, Grigoriadis S, Anagnostopoulos F, Spiliopoulos S
Medicina (Kaunas). 2024; 60(4).
PMID: 38674324
PMC: 11051965.
DOI: 10.3390/medicina60040678.
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment-In Vitro, In Vivo and Clinical Trials Literature Review.
Szulc A, Wozniak M
Cancers (Basel). 2024; 16(8).
PMID: 38672570
PMC: 11047913.
DOI: 10.3390/cancers16081483.
Low-Density Lipoproteins Increase Proliferation, Invasion, and Chemoresistance via an Exosome Autocrine Mechanism in MDA-MB-231 Chemoresistant Cells.
Castaneda-Sanchez C, Chimal-Vega B, Leon-Gutierrez R, Araiza-Robles A, Serafin-Higuera N, Pulido-Capiz A
Biomedicines. 2024; 12(4).
PMID: 38672098
PMC: 11048396.
DOI: 10.3390/biomedicines12040742.
and evaluation of novel chromeno[2,3-]pyrimidinones as therapeutic agents for triple negative breast cancer.
Carvalho L, Pedroso de Lima F, Cerqueira M, Silva A, Pontes O, Oliveira-Pinto S
RSC Med Chem. 2024; 15(4):1362-1380.
PMID: 38665823
PMC: 11042168.
DOI: 10.1039/d3md00682d.
NET-related gene signature for predicting AML prognosis.
Wang J, Wang H, Ding Y, Jiao X, Zhu J, Zhai Z
Sci Rep. 2024; 14(1):9115.
PMID: 38643300
PMC: 11032381.
DOI: 10.1038/s41598-024-59464-y.